Celldex Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Celldex Therapeutics

08/05/2025 21:24

Celldex Therapeutics Inc CLDX.OQ reported a quarterly adjusted loss of 81 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -56 cents.  The mean expectation of twelve analysts for the quarter was for a loss of 75 cents per share. Wall Street expected results to range from -92 cents to -59 cents per share.

Revenue rose 345.5% to $695.00 thousand from a year ago; analysts expected $1.05 million.

Celldex Therapeutics Inc's reported EPS for the quarter was a loss of 81 cents​.

The company reported a quarterly loss of $53.8 million.

Celldex Therapeutics Inc shares had risen by 4.2% this quarter and lost 25.2% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 2.6% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Celldex Therapeutics Inc is $60.00

This summary was machine generated from LSEG data May 8 at 08:24 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.75
-0.81
Missed
Dec. 31 2024
-0.73
-0.71
Beat
Sep. 30 2024
-0.67
-0.64
Beat
Jun. 30 2024
-0.59
-0.54
Beat